Tag: AstraZeneca oncology drugs

Home / AstraZeneca oncology drugs

Categories

Acalabrutinib with bendamustine and rituximab is approved by the USFDA for previously untreated mantle cell lymphoma

On January 16, 2025, the Food and Drug Administration granted conventional approval to acalabrutinib (Calquence, AstraZeneca) in combination with bendamustine and rituximab for adults with previously ...
astrazeneca-oncology-drugs

Scan the code